IMNN READ THE FULL IMNN RESEARCH REPORT Business Update OVATION 2 Translational Data Presented at ESMO On June 18, 2025, ...

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also ...

IMUNON, Inc. raises $3.25 million through the sale of shares and warrants, potentially totaling $9.75 million with full warrant exercise. IMUNON, Inc. has completed a private placement raising ...

Dr Lindborg shares her journey to her present role, the true potential shown in this new data for addressing unmet needs in ...

Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, ...

Imunon formally requested to retract its Form S-1 registration with the SEC after initially registering the document on April 4. The biotech firm's shares rose 4.1% to $0.42 on Thursday and surged ...

About IMNN-001 Immunotherapy Designed using IMUNON's proprietary TheraPlas ® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that ...

REGISTER HERE It is recommended that investors pre-register an LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development ...

LAWRENCEVILLE, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced the ...